ArticleCancer biology & therapy2016
PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.
Article in Cancer biology & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 9 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Influence ofJCO precision oncology · 2024Pooled it
- EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.Cancer immunology, immunotherapy : CII · 2022Pooled it
- Pooled it
- Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.Cancer biology & medicine · 2020Pooled it
- The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2019Pooled it
- Pooled it
- PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Scientific reports · 2017Pooled it
- Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.Oncotarget · 2017Pooled it
- The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.Oncotarget · 2017Pooled it
- EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.Technology in cancer research & treatmentTrial
- Deep learning multi-omics integration identifies new molecular subtypes of lung cancer.BioData mining · 2026Article
- ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer.World journal of surgical oncology · 2026Article
- EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Driver mutations and malignant pleural effusion in non-small cell lung cancer.BMC medical genomics · 2025Article
- Tumour- and Non-Tumour-Associated Factors That Modulate Response to PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer.Cancers · 2025Review
- The Efficacy of Immune Checkpoint Inhibitors in the EGFR Mutant and Wild-Type Non-Small Cell Lung Cancer Is Positively Associated With the Maturation and Abundance of Dendritic Cells.Thoracic cancer · 2025Article
- The challenge of cytotoxic T cell responses in carcinoma with a focus on lung carcinoma.Frontiers in oncology · 2025Review
- WFDC2 is a potential prognostic and immunotherapy biomarker in lung adenocarcinoma.The Journal of international medical research · 2024Article
- From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer.Frontiers in immunology · 2024Review
- Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.PloS one · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was aimed to detect the correlation among EGFR/KRAS status and PD-1/PD-L1 expression in non-small-cell lung cancer (NSCLC) patients. PD-1 and PD-L1 expressions were detected by immunohistochemistry in 100 surgically resected lung adenocarcinoma tissues and were statistically correlated with clinicopathological characteristics including EGFR and KRAS statuses. Besides, the overall survival (OS) times were analyzed. There was a statistical significances between PD-1 expression in tumor and KRAS status (P = 0.043), with a higher mutation rate in with lower PD-1 expression patients. There was a statistical significance between PD-L1 expression in tumor and EGFR status (P = 0.012), with a higher mutation rate in patients with lower PD-L1 expression. The OS of patients with EGFR mutation was significantly longer than those without EGFR mutation. The OS of patients with lower PD-L1 in tumor was significantly longer than those with higher PD-L1 expression. We found negative associations between PD-L1 expression in tumor and mutated EGFR status, as well as between PD-1 expression in tumor and mutated KRAS status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.